Blood, Data, and Decisions: A New Test Redefines MS Strategy

MENLO PARK, CA – July 08, 2026 – In the complex world of managing multiple sclerosis (MS), one of the most fraught decisions for both clinician and patient is judging whether new or worsening symptoms signal a true inflammatory attack or a temporary, non-threatening flare-up. This judgment call, often made under pressure with ambiguous information, dictates the use of powerful steroids and can trigger expensive, time-consuming MRI scans. Now, a new independent study is providing powerful evidence that a simple blood test can bring objective clarity to this critical crossroads, representing a significant strategic shift in neurological care.

Octave Bioscience, a precision neurology company, has been thrust into the spotlight with the publication of an investigator-initiated study in the peer-reviewed journal Neurology and Therapy. The research validates the company's Multiple Sclerosis Disease Activity (MSDA) Test, demonstrating its remarkable ability to distinguish a true MS relapse from a pseudoexacerbation. For the nearly one million Americans living with MS, this move from subjective assessment to data-driven insight marks a pivotal moment in their journey.

The Clinical Dilemma and a Data-Driven Solution

A pseudoexacerbation can mimic a true relapse, with symptoms like fatigue, weakness, or blurred vision flaring up due to factors like heat, stress, or infection, without new inflammatory damage to the central nervous system. Traditionally, distinguishing between the two has relied on a combination of clinical evaluation and MRI scans showing new gadolinium-enhancing lesions. This process can be slow, and MRIs, while a cornerstone of MS care, provide only periodic snapshots of structural change.

The new study, a retrospective analysis of 66 patients at a major academic medical center, puts hard numbers on the MSDA Test's diagnostic power. Using MRI-confirmed inflammatory activity as the gold standard, the test's Disease Activity Score identified true relapses with 100% sensitivity and 94% specificity. In strategic terms, this translates to an exceptionally low risk of missing a true relapse and a high degree of confidence that a low score correctly rules one out. The test's 100% negative predictive value means that when the test says there is no inflammatory relapse, clinicians can be certain of it.

"One of the greatest challenges in multiple sclerosis care is determining whether new or worsening symptoms reflect active inflammatory disease or a pseudoexacerbation," said Dr. Darin T. Okuda, lead author of the study and Professor of Neurology at The University of Texas Southwestern Medical Center. "These findings suggest that the MSDA Test may provide clinicians with additional objective information to complement clinical evaluation and MRI when assessing patients presenting with new symptoms."

Crucially, the test's multi-analyte approach, which measures 18 distinct protein biomarkers related to pathways like neuroinflammation and myelin biology, proved superior to single-biomarker tests. It significantly outperformed neurofilament light chain (NfL), a well-known but less specific indicator of neuronal injury, with an area under the curve (AUC) of 98.1% versus 82.8%. This demonstrates the strategic value of a comprehensive data model over a single, noisier data point.

From Lab Bench to Clinical Practice

For any diagnostic tool to be effective, it must be integrated seamlessly into the existing healthcare infrastructure. Octave Bioscience appears to have executed this phase of its strategy effectively through a key partnership with Quest Diagnostics. This collaboration makes the test accessible via a simple blood draw at any of Quest's 7,000 patient service centers nationwide, removing a significant logistical barrier for both patients and providers. With over 19,000 patient tests delivered since its 2022 launch, market adoption is clearly underway.

Perhaps most impactful from an operational standpoint is the test's timeliness. The study found that in acute cases, blood for the MSDA test was drawn before an MRI was performed 79% of the time, providing biological insights when decisions are most time-sensitive. This ability to deliver actionable data within days can fundamentally alter the diagnostic and treatment timeline, potentially avoiding weeks of uncertainty.

"Evidence continues to support blood-based biomarkers as an objective way to measure disease activity, and this study adds to the growing evidence supporting the MSDA Test in clinical practice," noted Terrie Livingston, Vice President of Medical Affairs at Octave Bioscience. This real-world evidence is critical; data from hundreds of providers shows the test is already influencing clinical decision-making regarding disease-modifying therapies in up to 44% of cases, a figure that rises with repeated testing.

The Patient Perspective and Economic Impact

Beyond the clinical and operational advantages, the strategic value of the MSDA test extends to patient experience and healthcare economics. The diagnostic uncertainty of MS creates immense anxiety. Providing a clear, objective answer quickly can empower patients and foster more confident, collaborative decisions with their neurologists.

Furthermore, the financial accessibility of the test has been a clear focus. Octave states that it accepts all insurance and offers a financial assistance program, "Octave Cares," designed to cap out-of-pocket costs for qualified patients, mitigating a common barrier to the adoption of novel diagnostics. This approach is vital for ensuring equitable access and driving widespread use.

From a health system perspective, the economic implications are profound. By accurately identifying patients who do not require immediate intervention, the test can help reduce the use of costly MRIs and potentially unnecessary courses of high-dose corticosteroids, which carry their own side effects and costs. Optimizing the timing and selection of expensive disease-modifying therapies based on objective biological activity, rather than symptoms alone, represents a major step toward value-based care in neurology.

A New Front in Precision Neurology

The validation of the Octave MSDA Test is not an isolated event but a key development in a much broader industry trend: the rise of precision neurology. The global market for these technologies was estimated at over $18 billion in 2025 and is projected to quadruple by 2035, driven by an explosion in biomarker research and AI-powered diagnostics. This test is a prime example of the shift from intermittent, structural imaging to more frequent, less invasive biological monitoring.

Octave Bioscience itself is looking beyond MS, with a research pipeline that includes work on Parkinson's disease, signaling that its multi-analyte biomarker platform is a foundational technology with broad applications. The ability to quantify the subtle, complex biology of neurodegenerative disease through a blood sample promises to revolutionize not just diagnosis, but long-term management, drug development, and clinical trial design. This data-first approach is poised to become the new strategic standard in managing complex, long-term neurological conditions.